Novozymes A/S B

Novozymes is a biotechnology company based in Denmark. Co.'s business operations are centered on the development of industrial enzymes, microorganisms, and biopharmaceutical ingredients. Co. provides business-to-business biological solutions used in the production of numerous products such as biofuel, detergents, feed, and crops. Co.'s business operations are organized along two segments: the Enzyme Business which is divided into four areas, providing industrial enzymes for household care, food & beverages, bioenergy, and feed & other technical; and the BioBusiness which is home to Co.'s microorganisms and biopharmaceutical ingredients.
  • TickerNZYM B
  • ISINDK0060336014
  • ExchangeNasdaq Nordic Copenhagen
  • SectorPharmaceuticals & Biotechnology
  • CountryDenmark

Analysts

Novozymes A S: 1 director sold

A director at Novozymes A S sold 765,000 shares at 318.970DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boa...

Nurhayati Wan

Novozymes

Nurhayati Wan

Novozymes

Rune Majlund Dahl

Novozymes (Sell, TP: DKK250.00) -

Novozymes (NZYMB DC, Sell) - (19 pages)

Anders Idborg ...
  • Bengt Jonassen
  • Daniel Thorsson
  • Erik Moberg
  • Fredrik Ivarsson
  • Haakon Amundsen
  • Jan Erik Gjerland
  • Mads Thinggaard
  • Magnus Andersson
  • Martin Melbye
  • Morten Raunholt Eismark
  • Olof Cederholm
  • Oskar Vikström
  • Peter Kurt Nielsen
  • Petter Nystrøm
  • Simon Granath
  • Stefan Knutsson
  • Tobias Kaj

Talking Points - Ringkjøbing Landbobank (Sell): Downgrading after strong run

ABB Ltd (Hold) Post-results comment: Less drama soothes, but no game changer New NII initiatives eaten by lower IP income ahead We downgrade to SELL (Hold); TP down to DKK 445 (455)

Morten Raunholt Eismark

Novozymes - Long-term guidance could be a tall order

Full Q3 report after PW pre-release and exit of CEO Positive surprise on adj. EBIT, FCF guidance seems safe We believe long-term guidance could be at risk

Novozymes A S: 1 director sold

A director at Novozymes A S sold 765,000 shares at 318.970DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boa...

Christoffer Wang Bjørnsen ...
  • Frank Maaø
  • Joachim Gunell
  • Jon Masdal
  • Karl-Johan Bonnevier
  • Martin Hoang Nguyen
  • Mattias Holmberg
  • Niclas Gehin
  • Nicolas McBeath
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Rune Majlund Dahl
  • Simen Mortensen
  • Tomi Railo

Northern Lights

Alexander Aukner ...
  • Niclas Gehin
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

Eivind Sars Veddeng ...
  • Håkon Astrup
  • Nicolay Dyvik
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Tomi Railo

Northern Lights

Eivind Sars Veddeng ...
  • Jimi Lehtonen
  • Jon Masdal
  • Martin Arnell
  • Martin Huseby Karlsen
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

Jesper Ingildsen ...
  • Joachim Gunell
  • Mattias Holmberg
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling
  • Rune Majlund Dahl

Northern Lights

Thanks to a better fundamental star rating, NOVOZYMES A/S sees an upgrade to Neutral

The independent financial analyst theScreener just awarded an improved star rating to NOVOZYMES A/S (DK), active in the Specialty Chemicals industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as moderately risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date October 15, 2019, the closing price was DKK 304.40 and its expected value was estimated at DKK 291.44.

Nurhayati Wan

Novozymes

Nurhayati Wan

Novozymes

Nurhayati Wan

Novozymes

Nurhayati Wan

Novozymes

MarketLine Department

Royal DSM N.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Royal DSM N.V. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Royal DSM N.V. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highl...

Novozymes – Proxinvest Corporate Governance Rating ® : C

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Expert Corporate Governance Service (ECGS)

Novozymes - February 27, 2019

In general, Novozymes is in compliance with the Danish regulations relating to the organisation and procedures of the Annual General Meeting. Under ITEM 5a, it is proposed to re-appoint Mr. Jorgen Buhl Rasmussen as Chairman of the board of directors. Although he is considered independent, ECGS notes that Mr. Buhl Rasmussen is currently chairing Novozymes' remuneration committee, which is not in accordance with its guidelines. As a consequence, ECGS normally would have recommended opposition. However, considering that the proxy card does not permit this, it recommends abstention instead. Unde...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch